Listen to the CME summary on the Virtual Hallway Podcast:
In her recent Virtual Hallway lecture, dermatologist Dr. Fareen Mussani reframed seborrheic dermatitis (SD) as a condition that’s both common and deeply impactful—far beyond the visible flakes. Affecting over 5% of the population (likely more), SD can cause significant itch, sleep disruption, and quality of life issues comparable to acne and rosacea.
More Than Skin-Deep
Dr. Mussani emphasized that SD is a chronic inflammatory disease involving skin barrier dysfunction, excess sebum, and malassezia yeast. It often shows up on the scalp, face, chest, and ears—and can easily be confused with other conditions like psoriasis, atopic dermatitis, or rosacea.
A New Option: Roflumilast Foam 0.3%
Traditionally, treatment has been piecemeal—steroids, antifungals, and shampoo regimens. But 2024 brings a promising new tool: Roflumilast Foam 0.3%, a non-steroidal topical approved for patients 9 and older. It’s well tolerated, works on the scalp, face, and body, and significantly improves both inflammation and itch in as little as 8 weeks.
Dr. Mussani’s takeaway: “You can stop when you’re clear, and restart at the first sign of a flare.” For patients and clinicians tired of cycling through ineffective OTC options, this streamlined approach could be a game-changer.
Watch the full lecture on Virtual Hallway for more on diagnosis tips, treatment comparisons, and practical pearls from Dr. Mussani.
Disclaimer: This post shares educational insights and does not replace personalized medical advice.